Search This Blog

Sunday, November 4, 2018

Medicare Plans to Phase in Changes for Office-Visit Payments


The Centers for Medicare & Medicaid Services (CMS) said it will phase in changes to payments to physicians for office visits, proceeding over the objection of many medical groups with its overhaul of reimbursement for evaluation and management (E&M) services.
CMS on Thursday released the final version of its 2019 update of the physician fee schedule. Through this rule, CMS plans to implement several documentation policy changes in 2019 and 2020, while holding off on others. For example, CMS will finalize codes for telehealth services related to home dialysis and acute stroke effective January 1, 2019.
But CMS said it will wait until 2021 to implement a simplification of payments for evaluation and management office/outpatient visits, delaying the start of the controversial proposal. CMS had planned to collapse the level 2 to 5 billing codes into one. It now plans to use a single rate for E&M office/outpatient-visit levels 2 through 4 for established and new patients, keeping level 5 in place to better account for the care and needs of complex patients. (Level 1 covers simpler tasks that can be handled by staff other than physicians.)
“We talked about going to two codes,” CMS Administrator Seema Verma said on a call with reporters on Thursday. “Now we are going to be going to three codes.”
In response to a question from a reporter about the delay in implementation of the E&M overhaul, Verma signaled the possibility for further changes in the proposal. Major medical groups have criticized the E&M proposal. Verma maintained that the intention with the overhaul of E&M codes is to reduce the administrative burden on physicians and give them more time with their patients. The extra implementation time for the E&M code overhaul will allow CMS to make needed changes in the plan, she said.
“It gives us an opportunity to continue to work with stakeholders,” Verma said on the call.  “We know that this is going to have a tremendous impact on many doctors in America. We want to make sure that we get it right.”
Still, Verma appears unwilling to see the entire E&M overhaul derailed, as sometimes happens with CMS proposals that face significant opposition. In response to a reporter’s question about whether Verma would support Medicare scrapping the planned changes and sticking with the current five-level system, she replied, “No.”
Verma then added that the E&M system “hasn’t been updated in the last 20 years.”
“We’ve heard from providers across the nation that the current system is not working well,” Verma said. “There’s been a lot of discussion for many years and no one’s done anything. This administration is committed to addressing physician concerns, addressing burnout.”

Drug Payments

Also on Thursday, CMS said it is proceeding with its plan to shave the initial payment for newly introduced drugs that are administered by physicians and thus covered by the Part B program.
So, next year Medicare will change its formula for initial payments for new drugs, shaving the premium to the wholesale acquisition costs (WAC) to 3% for the first 3 months down from the current 6%. Medicare uses WAC as a temporary benchmark. In general, it applies a premium to the reported average sales price of drugs as the benchmark. On the call, Verma said this change is part of the Trump administration’s attempts to rein in drug costs. Groups, including the Pharmaceutical Research and Manufacturers of America, have opposed this reduction in payment
Yet, on this proposal, CMS has an influential supporter. In a comment on the draft physician fee rule, the Medicare Payment Advisory Commission (MedPAC) said that it supports CMS’s plan for lowering the add-on payment for newly introduced drugs. Lawmakers and their staff members often consider MedPAC’s work in deciding how to respond to CMS’s initiatives.
“As the Commission noted in its June 2017 report to the Congress, reducing the add-on for certain WAC-priced drugs is a modest, positive step toward lowering drug costs for beneficiaries and the Medicare program,” wrote MedPAC Chairman Francis J. Crosson in a September 4 letter to CMS.
AMA Shows Support
The American Medical Association (AMA) offered a quick assessment of the final rule, thanking CMS for not proceeding in 2019 with the collapse of the E&M codes.
“A two-year window for implementation of the proposal will give the AMA-convened work group — comprised of physicians and other health professionals — time to make recommendations on this complicated topic,” said Barbara L. McAneny, MD, president of the AMA, in a statement.
The AMA panel, which includes members of various specialties, is analyzing these E&M coding issues and plans to work with CMS and the Trump administration on the overhaul. AMA also thanked CMS for other aspects of the physician fee rule, such as a move to eliminate the requirement for physicians to redocument information that has already been documented in the patient’s record by practice staff or by the patient. The AMA also said it was pleased that CMS declined to advance a proposal to reduce payment for office visits when performed on the same day as another service.

Halting the Osteoarthritis Upswell


Osteoarthritis (OA) is a leading cause of pain and disability among adults — and has doubled in prevalence over the past 70 years. Current numbers from the Arthritis Foundation tell it all:
  • 54 million adults in the U.S. have physician-diagnosed arthritis
  • By 2040, that number is expected to rise to 78.4 million
  • Among people over 65, one in two men is likely to have arthritis, as are two in three women
  • Arthritis is the leading cause of disability among adults in the U.S.
  • In 2013, medical costs and earning losses totaled $304 billion
A major challenge today in OA is understanding the disease, why its prevalence has increased so markedly — and what can be done to halt this trend.
Pain and the Joint
Despite these alarming figures, few effective treatments for OA exist, and there are no approved disease-modifying drugs that can help prevent progression.
Recent years have seen a shift in the understanding of OA, which was once considered a disease of wear-and-tear associated with aging. Today, however, increasing evidence exists indicating that low-grade inflammation is a contributing factor and that the condition is a disorder of the whole joint. Pain, which in OA is exacerbated by activity, is what usually leads patients to seek medical care. However, there is considerable discordance between the pain experienced by patients and the structural pathology.
“The signature feature of OA is cartilage loss, but the disease is a lot more than that — it winds up affecting all structures of the joint and causing lots of pain in ways we really don’t understand very well,” said David T. Felson, MD, of Boston University School of Medicine, in an interview.
Excess body fat clearly contributes to the development of OA, with mechanical excess loading affecting the weight-bearing joints but also through the production and proliferation of pro-inflammatory cytokines such as tumor necrosis factor, interleukin (IL)-6, and IL-1 by adipose tissue.
A Mismatch Disease
A novel study led by Daniel E. Lieberman, PhD, chair of the department of human evolutionary biology at Harvard University in Boston, suggested that viewing OA in an evolutionary context could shed light on its changing prevalence and risk factors. He defined OA as a “mismatch disease.”
“A mismatch disease is either more common or more severe today because our bodies are inadequately or imperfectly adapted to novel environmental conditions,” Lieberman told MedPage Today.
“The concept of mismatching is not unusual in biology — species are constantly being exposed to changes in the environment, and natural selection is always acting on mismatches. But what’s happening now is that we are changing our world so fast and so powerfully through cultural evolution that mismatches are becoming more common,” he explained.
The contributions of increased longevity and obesity became accepted as primary drivers of the recent increase in OA, but this hypothesis had never been fully tested. So Lieberman and colleagues conducted a study in which they compared rates of late-stage knee OA in postindustrial individuals (late 20th and early 21st centuries) with rates in the early industrial era (19th to early 20th centuries), and also in archaeological skeletons of prehistoric Native American hunter gatherers and farmers (approximately 2000 BC to 1700 AD).
The postindustrial group included 819 individuals who died between 1976 and 2015 in Albuquerque and Knoxville, while the early industrial group consisted of 1,581 people who died from 1905 to 1940 in St. Louis and Cleveland. The prehistoric group included 176 skeletons from archaeological sites throughout the U.S. who were estimated to be ages ≥50 at the time of death. Late-stage knee OA can be identified in skeletal remains because of a pathologic process known as eburnation, a sclerotic polishing of subchondral bone resulting from bone-on-bone contact following loss of cartilage in the knee joint.
‘Astonishing’ Results
When the researchers compared the rates of knee OA in the three groups, the results were “astonishing,” according to Lieberman. After controlling for age and sex, the prevalence in the postindustrial group was 16% (95% CI 14%-19%), which was 2.6 times higher than in the early industrial sample (6%, 95% CI 5%-7%, P<0.001) and twice as high as in the prehistoric group (8%, 95% CI 5%-13%).
In addition, among the postindustrial patients with OA, 42% had both knees affected, which was a rate 2.5-fold higher than in the prehistoric group (17%, P=0.042) and 1.4-fold higher than in the early industrial group (30%, P=0.058).
At the time of death, individuals in the postindustrial group were 6 years older than the early industrial individuals, and their BMI was 41% higher. In the early industrial group, only 1% were obese and 6% were overweight, compared with 25% and 24%, respectively, of those in the postindustrial group (P<0.001).
Yet after adjusting for age and BMI, the prevalence of knee OA in the postindustrial sample (11%, 95% CI 8%-14%) was still 2.1 times higher than in the early industrial group (5%, 95% CI 4%-7%, P<0.01), Lieberman and colleagues reported in Proceedings of the National Academy of Sciences.
“These data show that knee OA long existed at low frequencies, but since the mid-20th century, knee OA has approximately doubled in prevalence, even after accounting for the effects of age and BMI,” they wrote.
Other factors that may have contributed, they proposed, include walking on hard pavements and in certain types of shoes, modern diets that include highly refined carbohydrates, and, in particular, lower physical activity, which is associated with thinner cartilage and lower cartilage proteoglycan content and is far more common today than in the past.
“From an evolutionary perspective, knee OA thus fits the criteria of a mismatch disease that is more prevalent or severe because our bodies are inadequately or imperfectly adapted to modern environments. Intriguingly, other well-studied mismatch diseases such as hypertension, atherosclerotic heart disease, and type 2 diabetes, that also have become epidemic during the last few decades are strongly associated with knee OA,” the researchers observed.
“There needs to be a large shift in how we think about these diseases of aging,” Lieberman said in an interview. “We are conflating diseases that are caused by aging with diseases that occur more commonly as you age. That’s a very serious conflation that we should stop doing.”
The focus should not be exclusively on treating OA, which is a highly debilitating disease with no cure apart from replacing the joint. “I’m not saying we shouldn’t treat people with OA. Obviously we should, but we also need to really think about how to prevent the disease. We’re not doing that right now, and that’s where an evolutionary perspective can really help,” he concluded.

Biotech week ahead, Nov. 5


Biotech earnings news flow accelerated in last week, with Pfizer Inc. (NYSE: PFE) and Sanofi SA (NYSE: SNY) among the noteworthy releases of the week.
With the earnings news flow set to continue, these are some of the catalysts biotech investors should watch for in the upcoming week.

Conferences

  • 28th World Congress on Cardiology and Heart Diseases: Nov. 5-6 in Amsterdam, Netherlands
  • 5th International Conference on Depression, Anxiety and Stress Management: Nov. 5-6 in Bangkok, Thailand
  • 23rd Annual Congress on Pediatrics & Neonatology: Nov. 5-6 in Bangkok
  • International Conference on Bipolar Disorder: Depression and Psychiatry: Nov. 5-6 in Abu Dhabi, UAE
  • World Summit on Liver Cirrhosis and Hepatitis: Nov. 7-8 in Singapore City
  • Global Congress on Asthma, Allergy and Immunology: Nov. 7-8 in Singapore City
  • International Conference on Frontiers in Gynecologic Cancers: Nov. 7-8 in Singapore City
  • Global Congress on Asthma, Allergy and Immunology: Nov. 7-8 in Singapore City
  • The Society for Immunotherapy of Cancer, or SITC Annual Meeting: Nov. 7-11 in Washington, D.C.
  • 24th Asia-Pacific Dermatology Conference: Nov. 8-9 in Sydney, Australia
  • American Medical Association 2018 Interim Meeting: Nov. 8-13 in National Harbor, Maryland
  • 2nd Annual Summit on Cell Therapy, Tissue Science and Regenerative Medicine: Nov. 9-10 in Atlanta
  • 2nd Annual Summit on Stem Cell Research, Cell and Gene Therapy: Nov. 9-10 in Atlanta
  • The American Association for the Study of Liver Diseases, or AASLD, 2018 Liver Meeting: Nov. 9-13 in San Francisco

PDUFA Dates

Merck & Co., Inc. (NYSE: MRK), which recently announced FDA approval for its Keytruda in combination with chemotherapy drugs for metastatic squamous non-small cell lung cancer, or NSCLC, has another tryst with the FDA on Friday, Nov. 9. The regulatory body will announce its verdict on Keytruda as a monotherapy for hepatocellular carcinoma. The sBLA was submitted based on the KEYNOTE-224 study.

Clinical Trial Results

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will release Phase 2 longer-term 42-month data on its achondroplasia treatment Vosoritide Wednesday, Nov. 7.
Novartis AG (NYSE: NVS) will present Phase 3 data for its heart failure pipeline candidate Entresto at the AHA 2018 meeting to be held between Nov. 10 and 12.
Eidos Therapeutics Inc (NASDAQ: EIDX) will release Phase 2 data for AG10, its treatment candidate for transthyretin amyloidosis, on Saturday, Nov. 10.

SITC 2018 Meeting Presentations

Iovance Biotherapeutics Inc (NASDAQ: IOVA): update on Phase 2 program for LN-144 for treating refractory metastatic melanoma (Nov. 9).
Aduro BioTech Inc (NASDAQ: ADRO): initial Phase 1b data for its ADU-S100 for treating solid tumors as well as lymphoma (Nov. 9).
TESARO Inc (NASDAQ: TSRO): Phase 1 data for its solid tumor treatment combo TSR-022 plus TSR-042 (Nov. 9) as well as Phase 1 data for another solid tumor treatment candidate, TSR-033 (Nov. 7-11).
Nektar Therapeutics (NASDAQ: NKTR): Updated Phase 1/2 data for NKTR-214 plus Bristol-Myers Squibb Co (NYSE: BMY)’s Opdiva for melanoma and renal cell carcinoma and NSCLC (Nov. 9).
Corvus Pharmaceuticals Inc (NASDAQ: CRVS): Phase 2 data for its solid tumor treatment candidate CPI-444 (Nov. 10).
Leap Therapeutics Inc (NASDAQ: LPTX): Interim Phase 1 data for its TRX518 in combination with KEYTRUDA or Opdivo for treating advanced solid tumors (Nov. 7-11).

Earnings

Monday
  • Amicus Therapeutics, Inc. (NASDAQ: FOLD) (before the market open)
  • Avadel Pharmaceuticals PLC (NASDAQ: AVDL) (before the market open)
  • Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open)
  • Alder Biopharmaceuticals Inc (NASDAQ: ALDR) (after the market close)
  • Alimera Sciences Inc (NASDAQ: ALIM) (after the market close)
  • Akcea Therapeutics Inc (NASDAQ: AKCA) (after the market close)
  • Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the market close)
  • Dynavax Technologies Corporation (NASDAQ: DVAX) (after the market close)
  • PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the market close)
  • Insys Therapeutics Inc (NASDAQ: INSY) (after the market close)
  • Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the market close)
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (after the market close)
  • Kura Oncology Inc (NASDAQ: KURA) (after the market close)
  • Mylan NV (NASDAQ: MYL) (after the market close)
  • Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) (after the market close)
  • Xencor Inc (NASDAQ: XNCR) (after the market close)
  • Evolus Inc (NASDAQ: EOLS) (after the market close)
  • Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) (after the market close)
  • Otonomy Inc (NASDAQ: OTIC) (after the market close)
  • Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (after the market close)
Tuesday
  • ANI Pharmaceuticals Inc (NASDAQ: ANIP) (before the market open)
  • Eli Lilly And Co (NYSE: LLY) (before the market open)
  • Becton Dickinson and Co (NYSE: BDX) (before the market open)
  • BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open)
  • Chimerix Inc (NASDAQ: CMRX) (before the market open)
  • InspireMD Inc (NYSE: NSPR) (before the market open)
  • SAGE Therapeutics Inc (NASDAQ: SAGE) (before the market open)
  • Spark Therapeutics Inc (NASDAQ: ONCE) (before the market open)
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the market open)
  • Mallinckrodt PLC (NYSE: MNK) (before the market open)
  • Neuronetics Inc (NASDAQ: STIM) (before the market open)
  • Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open)
  • Ionis Pharmaceuticals Inc (NASDAQ: IONS) (before the market open)
  • Haemonetics Corporation (NYSE: HAE) (before the market open)
  • Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open)
  • Adaptimmune Therapeutics PLC (NASDAQ: ADAP) (before the market open)
  • Aquestive Therapeutics Inc (NASDAQ: AQST) (after the market close)
  • Accelerate Diagnostics Inc (NASDAQ: AXDX) (after the market close)
  • Aclaris Therapeutics Inc (NASDAQ: ACRS) (after the market close)
  • Audentes Therapeutics Inc (NASDAQ: BOLD) (after the market close)
  • Aerie Pharmaceuticals Inc (NASDAQ: AERI) (after the market close)
  • CytomX Therapeutics Inc (NASDAQ: CTMX) (after the market close)
  • Iovance Biotherapeutics Inc (NASDAQ: IOVA) (after the market close)
  • Theravance Biopharma Inc (NASDAQ: TBPH) (after the market close)
  • Cara Therapeutics Inc (NASDAQ: CARA) (after the market close)
  • Xenon Pharmaceuticals Inc (NASDAQ: XENE) (after the market close)
  • Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) (after the market close)
  • Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (after the market close)
  • Five Prime Therapeutics Inc (NASDAQ: FPRX) (after the market close)
  • Genomic Health, Inc. (NASDAQ: GHDX) (after the market close)
  • Myriad Genetics, Inc. (NASDAQ: MYGN) (after the market close)
  • Halozyme Therapeutics, Inc. (NASDAQ: HALO) (after the market close)
  • Inspire Medical Systems Inc (NYSE: INSP) (after the market close)
  • Paratek Pharmaceuticals Inc (NASDAQ: PRTK) (after the market close)
  • Supernus Pharmaceuticals Inc (NASDAQ: SUPN) (after the market close)
  • CytomX Therapeutics Inc (NASDAQ: CTMX) (after the market close)
  • Immune Design Corp (NASDAQ: IMDZ) (after the market close)
  • CymaBay Therapeutics Inc (NASDAQ: CBAY) (after the market close)
  • DexCom, Inc. (NASDAQ: DXCM) (after the market close)
  • Fulgent Genetics Inc (NASDAQ: FLGT) (after the market close)
Wednesday
  • Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (before the market open)
  • Affimed NV (NASDAQ: AFMD) (before the market open)
  • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (before the market open)
  • Amneal Pharmaceuticals Inc (NYSE: AMRX) (before the market open)
  • Protalix Biotherapeutics Inc (NYSE: PLX) (before the market open)
  • Intra-Cellular Therapies Inc (NASDAQ: ITCI) (before the market open)
  • Evofem Biosciences Inc (NASDAQ: EVFM) (before the market open)
  • Melinta Therapeutics Inc (NASDAQ: MLNT) (before the market open)
  • Recro Pharma Inc (NASDAQ: REPH) (before the market open)
  • Charles River Laboratories Intl. Inc (NYSE: CRL) (before the market open)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA) (before the market open)
  • Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) (before the market open)=
  • Horizon Pharma PLC (NASDAQ: HZNP) (before the market open)
  • Miragen Therapeutics Inc (NASDAQ: MGEN) (before the market open)
  • Pieris Pharmaceuticals Inc (NASDAQ: PIRS) (before the market open)
  • Merrimack Pharmaceuticals Inc (NASDAQ: MACK) (before the market open)
  • TRACON Pharmaceuticals Inc (NASDAQ: TCON) (after the market close)
  • Zafgen Inc (NASDAQ: ZFGN) (after the market close)
  • MacroGenics Inc (NASDAQ: MGNX) (after the market close)
  • G1 Therapeutics Inc (NASDAQ: GTHX) (after the market close)
  • Regenxbio Inc (NASDAQ: RGNX) (after the market close)
  • Viking Therapeutics Inc (NASDAQ: VKTX) (after the market close)
  • Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) (after the market close)
  • Achieve Life Sciences Inc (NASDAQ: ACHV) (after the market close)
  • Avalara Inc (NYSE: AVLR) (after the market close)
  • Arbutus Biopharma Corp (NASDAQ: ABUS) (after the market close)
  • Aileron Therapeutics Inc (NASDAQ: ALRN) (after the market close)
  • Calithera Biosciences Inc (NASDAQ: CALA) (after the market close)
  • Kindred Biosciences Inc (NASDAQ: KIN) (after the market close)
  • Nektar Therapeutics (NASDAQ: NKTR) (after the market close)
  • Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the market close)
  • Immunomedics, Inc. (NASDAQ: IMMU)
  • Glaukos Corp (NYSE: GKOS) (after the market close)
  • Editas Medicine Inc (NASDAQ: EDIT) (after the market close)
  • Flexion Therapeutics Inc (NASDAQ: FLXN) (after the market close)
  • Ocular Therapeutix Inc (NASDAQ: OCU) (after the market close)
  • Hologic, Inc. (NASDAQ: HOLX) (after the market close)
  • Pfenex Inc (NYSE: PFNX) (after the market close)
  • Voyager Therapeutics Inc (NASDAQ: VYGR) (after the market close)
  • Portola Pharmaceuticals Inc (NASDAQ: PTLA) (after the market close)
  • TherapeuticsMD Inc (NASDAQ: TXMD) (after the market close)
Thursday
  • Karyopharm Therapeutics Inc (NASDAQ: KPTI) (before the market open)
  • Histogenics Corp (NASDAQ: HSGX) (before the market open)
  • Ligand Pharmaceuticals Inc. (NASDAQ: LGND) (before the market open)
  • Obseva SA (NASDAQ: OBSV) (before the market open)
  • Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) (before the market open)
  • Endo International PLC (NASDAQ: ENDP) (before the market open)
  • Foamix Pharmaceuticals Ltd (NASDAQ: FOMX) (before the market open)
  • Misonix, Inc. (NASDAQ: MSON) (after the market close)
  • Assertio Therapeutics Inc (NASDAQ: ASRT) (after the market close)
  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (after the market close)
  • BioTime, Inc. (NYSE: BTX) (after the market close)
  • Coherus Biosciences Inc (NASDAQ: CHRS) (after the market close)
  • CareDx Inc (NASDAQ: CDNA) (after the market close)
  • Synthetic Biologics Inc (NYSE: SYN) (after the market close)
  • Vermillion, Inc. (NASDAQ: VRML) (after the market close)
  • ICU Medical, Incorporated (NASDAQ: ICUI) (after the market close)
  • Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the market close)
  • Transenterix Inc (NYSE: TRXC) (after the market close)
  • Collegium Pharmaceutical Inc (NASDAQ: COLL) (after the market close)
  • DENTSPLY SIRONA Inc (NASDAQ: XRAY) (after the market close)
  • HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the market close)
  • Organovo Holdings Inc (NASDAQ: ONVO) (after the market close)
Friday
  • SurModics, Inc. (NASDAQ: SRDX) (before the market open)
  • PLx Pharma Inc (NASDAQ: PLXP) (before the market open)
IPO Quiet Period Expiry
Allogene Therapeutics, Inc. (NASDAQ: ALLO)
Equillium, Inc. (NASDAQ: EQ)

Saturday, November 3, 2018

Hospital bankruptcies skyrocketed in past 2 years


The healthcare industry’s level of “distress” is far higher than in the broader economy, according to a new report.
The latest Polsinelli-TrBK Distress Indices for healthcare, which uses Chapter 11 bankruptcy filings for entities with $1 million or more in assets to determine “distress” levels, found that 20 hospitals have filed since 2016.
About 3 out of 4 of hospitals that filed bankruptcy were in rural areas.
Chapter 11 filings have decreased by 53% nationwide since 2010, according to the report. But in healthcare, its distress scores increased by 305% in that same window.
“I think it’s going to be full speed ahead for a while,” Jeremy Johnson, the report’s editor and a bankruptcy and restructuring attorney at Polsinelli, told FierceHealthcare. “The biggest issue is that no problem has been solved—the issues in healthcare we don’t think are cyclical.”
The index gave healthcare a 405 score for this quarter, which marks an increase of 65 points from the second quarter of 2018. By comparison, the real estate industry earned a 31.67 index from Polsinelli.
Healthcare’s score has jumped in eight of the past 11 quarters, according to the analysis. Each quarterly index includes a year’s worth of data.
Healthcare trends are “decoupled” from broader economic trends, as its structure and complexities are unique from most other industries, Johnson said. And there’s no end in sight for the problems plaguing the industry, he said.
The top issues contributing to the trend are tort liability, government reimbursement and a variety of management problems, Johnson said. These concerns are especially impacting providers in the southwest, according to the report.
For example, Neighbors Legacy Holdings, a Houston-based provider with more than 30 freestanding emergency departments across the state, filed for bankruptcy this year after increased competition, payer pressures and overextending its growth shrunk margins, according to the report.
Falling reimbursement rates are also coupled with increased uninsured rates, a pairing that spells bad news for rural providers, according to the report.
“That’s not a good formula for staying alive,” Johnson said.
Despite the risk of overexpansion, healthcare doesn’t seem poised to slow down on consolidation any time soon.
Fitch Ratings said in its latest credit report that healthcare’s ratings are stable—for now. The industry’s continued obsession with mergers and acquisitions is causing its long-term credit projections to slip, Fitch said.
“Prospects of enhanced cash flow generation and greater efficiencies of scale are not fulling offsetting increased leverage, and this is altering the long-term credit risk profile of the sector,” according to the analysis.

Fed judge shuts firm that collected more than $100M for sham health plans


A federal court has temporarily shut down a sham health insurer that collected more than $100 million from consumers and left tens of thousands of people uninsured.
The South Florida company called Simple Health Plans LLC sold “worthless” plans to consumers, according to the Federal Trade Commission (FTC), which asked a U.S. District Court to halt the company’s operations while it seeks to permanently shut down the company. The agency said many consumers who purchased the sham coverage were left with substantial medical expenses and thousands of dollars in unpaid bills.
In a complaint (PDF) filed by the FTC, prosecutors alleged Simple Health Plans owner Steven J. Dorfman, who operated four other companies, preyed on consumers seeking health insurance beginning in 2013 through a network of lead-generation websites touting comprehensive, ACA-compliant coverage. In advertising materials, the company falsely claimed to be affiliated with AARP and the Blue Cross Blue Shield Association.

“Many consumers were misled into thinking they had purchased comprehensive health insurance, but when they needed to rely on that insurance, they learned they had none of the promised benefits,” Andrew Smith, the director of the FTC’s Bureau of Consumer Protection, said in a statement. “The plans defendants were selling are not health insurance and they aren’t a substitute for health insurance.”
Consumers that submitted information on websites like “obamacare-plans.com” and “trumpcarequotes.com”—which billed itself as “health insurance for smart people”—were connected to a telemarketer working for Simple Health Plans that falsely claimed to be a registered insurance agent. Some paid as much as $500 a month for insurance that provided little to no coverage.
Often the plans offered just $100 per day for hospitalization and a maximum benefit of $3,200, and only for hospital stays of 30 days or more. An undercover FTC investigator was sold a plan that claimed to cover diabetes medications for $4 to $12 but actually cost $850-$900.
Additionally, some consumers were subject to the individual mandate penalty for failing to purchase coverage that met ACA coverage requirements. A preliminary injunction hearing is scheduled for later this month.

For heart patients who want to live longer: Move every 20 minutes


Heart patients should move around every 20 minutes during an eight-hour period of sitting, according to a paper presented on Saturday at the Canadian Cardiovascular Congress in Toronto, an event where visiting experts from the European Society of Cardiology participate in joint scientific sessions with the Canadian Cardiovascular Society.
Heart patients spend most of their waking hours sitting, lying down, but remaining sedentary for long periods could shorten their life, research suggests. Taking breaks and burning more than 770 calories per day should help prolong their life, said Ailar Ramadi, postdoctoral fellow in the Faculty of Rehabilitation Medicine at University of Alberta, Edmonton, and author of the latest paper.
He suggests simple activities such as standing up and walking at a casual pace. “There is a lot of evidence now that sitting for long periods is bad for health,” Ramadi said. His study enrolled 132 patients with coronary artery disease and an average age of 63 years; 77% were men. Participants wore an arm band activity monitor for an average of 22 hours a day for five days.

This is not the first doctor to effectively recommend walking your way to a longer life. Walking at an average pace was linked to a 20% reduction in the risk of mortality compared with walking at a slow pace, according to a study published earlier this year in the British Journal of Sports Medicine. A similar result was found for risk of dying from cardiovascular disease.
That study was a collaboration between the Universities of Sydney, Cambridge, Edinburgh, Limerick and Ulster. It linked mortality records with the results of 11 population-based surveys in the U.K. between 1994 and 2008 in which participants reported their walking pace. Average pace walkers aged 60 years or over experienced a 46% reduction in risk of death from cardiovascular causes.
separate Harvard University study concluded that you could add 10 years to your life by eating a healthy diet, exercising 30 minutes or more a day, maintaining a healthy weight — a body mass index between 18.5 and 24.9 — never smoking and drinking only a moderate amount of alcohol. It analyzed 34 years of data from 78,000 women and 27 years of data from 44,000 men.